Interestingly, treatment with temozolomide —a DNA-alkylating agent that is used as standard therapy for patients with malignant gliomas that does not recruit TEMs or induce an invasive glioma phenotype [15]—did not increase Ang2 expression (Figure 1D). This evidence concerns the gene ANGPT2 and glioma.